These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 10499595)

  • 1. The oral fluoropyrimidines in cancer chemotherapy.
    Lamont EB; Schilsky RL
    Clin Cancer Res; 1999 Sep; 5(9):2289-96. PubMed ID: 10499595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
    Milano G; Ferrero JM; François E
    Br J Cancer; 2004 Aug; 91(4):613-7. PubMed ID: 15280932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oral fluorinated pyrimidines.
    de Bono JS; Twelves CJ
    Invest New Drugs; 2001; 19(1):41-59. PubMed ID: 11291832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral therapy for colorectal cancer: how to choose.
    Damjanov N; Meropol NJ
    Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral fluoropyrimidine treatment of colorectal cancer.
    Eng C; Kindler HL; Schilsky RL
    Clin Colorectal Cancer; 2001 Aug; 1(2):95-103. PubMed ID: 12445367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral DPD-inhibitory fluoropyrimidine drugs.
    Diasio RB
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oral fluoropyrimidines in the treatment of colorectal carcinoma].
    Porschen R
    Dtsch Med Wochenschr; 2003 Jun; 128 Suppl 2():S121-3. PubMed ID: 12817344
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
    Iqbal S; Lenz HJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):947-55. PubMed ID: 15606325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral fluoropoyrimidines.
    Hoff PM; Royce M; Medgyesy D; Brito R; Pazdur R
    Semin Oncol; 1999 Dec; 26(6):640-6. PubMed ID: 10606257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UFT: mechanism of drug action.
    Köhne CH; Peters GJ
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):13-8. PubMed ID: 11098484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
    Schöffski P
    Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xeloda in colorectal cancer.
    Cassidy J
    Int J Clin Pract; 2001 Jun; 55(5):326-8. PubMed ID: 11452682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
    Shirasaka T; Taguchi T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correct fluorouracil (5-FU) half-life comparator for a 5-FU prodrug plus a dihydropyrimidine dehydrogenase inhibitor.
    White RM
    J Clin Oncol; 2001 Jun; 19(11):2970. PubMed ID: 11387375
    [No Abstract]   [Full Text] [Related]  

  • 17. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
    Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
    Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral fluoropyrimidines: a closer look at their toxicities.
    Macdonald JS
    Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
    Fukushima M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
    Hosokawa A
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():352-5. PubMed ID: 14574911
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.